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ABSTRACT
SEEMA MURUGAN: DETECTION AND CHARACTERIZATION OF D-9TETRAHYDROCANNIBINOL AND NOVEL SYNTHETIC CANNABINOID
METABOLITES USING HUMAN LIVER MICROSOMES
(Under the direction of Dr. Murrell Godfrey)
Marijuana and synthetic cannabinoids are the most commonly used and trafficked illicit
drug. ∆9-tetrahydrocannabinol (THC) is the primary active compound in marijuana. Synthetic
cannabinoids were created as a method to study the effects of cannabinoids on the endocannabinoid
system, which consists of endogenous cannabinoids, cannabinoid receptors, and the synthetic and
degrading enzymes responsible for the synthesis and degradation of endocannabinoids.
Cannabinoids activate the same receptors as endocannabinoids. Synthetic cannabinoids gained
popularity as recreational drugs due to their ability to avoid detection. Synthetic cannabinoids have
been found to have a greater binding affinity to the cannabinoid CB1 receptor than THC. They are
also shown to have a greater affinity at the CB1 receptor than the CB2 receptor. With the current
legalization status of marijuana for both recreational and medicinal use, it is important to know the
effects that these compounds can have on the body. The purpose of this experiment was to
characterize the metabolites of THC and three other synthetic cannabinoids metabolized by human
liver microsomes. The three synthetic cannabinoids chosed for this project are JWH-302, JWH237, and mepirapim. These cannabinoids are all related to very popular synthetic cannabinoids.
An AB SCIEX 3200 mass spectrometer (LC/MS/MS) in multiple reaction monitoring (MRM)
mode with electrospray ionization (ESI) was used to characterize the metabolites. This is part of a
bigger project that aims to use rat models to find the effects of THC and synthetic cannabinoids
on the cardiovascular and renal systems.
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INTRODUCTION
Four patients were evaluated at the University of Mississippi Medical Center on April 2,
2015 for delirium after the use of synthetic cannabinoids. Over the next couple of days, 24 more
patients were assessed with similar symptoms related to synthetic cannabinoid use. There was a
statewide alert requesting that health care providers report suspected cases of synthetic
cannabinoid use and intoxication to the Mississippi Poison Control Center (MPCC) after the death
of a patient. A patient showing at least two of the symptoms—sweating, psychosis, and severe
agitation—was considered a suspected case. Another statewide alert was issued after eleven days,
instructing all Mississippi emergency departments to submit lists of suspected patients to MPCC
every day. There were approximately 400 reported cases, which included eight deaths all linked
to synthetic cannabinoid use (Kasper et al., 2015). The outbreak of hospitalization related to
synthetic cannabinoid use in Mississippi was part of a larger multistate outbreak (Law et al. 2015).
This was the largest outbreak of the adverse effects related to synthetic cannabinoid use recorded
(Drenzek et al. 2013, Ghosh et al. 2013, & Murphy et al., 2013).
The debate on the legalization of marijuana in the United States received significant media
attention in 2012 (Wang et al., 2013). Marijuana prohibition began 80 years ago when the federal
government banned the sale, cultivation, and use of the cannabis plant. At a federal level, it remains
illegal (Berke, 2019). Public opinion has shifted dramatically towards support for the legalization
of marijuana (Galston & Dionne, 2013). Two-thirds of Americans say that the use of marijuana
should be legal, and the share of American adults who opposed legalization has fallen 20% since
2010 (Daniller, 2019). Support is especially strong among the younger generations, and those 65
and older staunchly oppose the legalization of marijuana. The proportion of Americans who see
marijuana as a gateway drug is steadily decreasing (Galston & Dionne, 2013). Marijuana has been
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legalized for recreational and medical use in 11 states for adults over the age of 21 and legalized
for medical use in 33 states (Berke, 2019).
The Colorado state constitution was modified in November 2000 in order to allow for the
use of medical marijuana for patients with chronic incapacitating medical conditions. Few patients
were using medical marijuana until the US Attorney General created guidelines for the federal
prosecution of the possession and use of marijuana. Jurisdiction of marijuana law enforcement was
given to the state government. This meant that medical marijuana licenses could be issued without
an expiration date to anyone with one of the conditions outlined in the Colorado law. This
drastically increased the number of licenses from 2008 to 2014 (Monte et al., 2015). The increased
availability of marijuana has led to increased health care problems related to marijuana exposure
(Wang et al., 2013). The scope of the problem with marijuana use is often difficult to fully quantify
because there are often other factors involved (Monte et al., 2015).
The rising prevalence of marijuana and other synthetic cannabinoids has become an issue
because the potential health effects associated with their use are still unclear. The legalization of
marijuana has increased opportunities for scientists to study the positive and negative effects of
marijuana, but the federal designation of marijuana as a schedule 1 drug limits the quality and
scope of trials that researchers can conduct (Monte et al., 2015). With policies moving towards the
legalization of cannabis, the adverse health effects are a source of controversy. Most policies have
been framed by the media as being either wholly harmless or harmful, without a complete
understanding of the effects of marijuana (Hall, 2009). Marijuana has been advocated for its
medicinal value because of the activity of ∆9-tetrahydrocannabinol (THC). The rapid absorption
of THC occurs with cannabis smoking, as THC is detectable in the plasma seconds after the first
smoke of a marijuana cigarette (ElSohly et al., 2018).
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∆9-tetrahydrocannabinol is the primary psychoactive compound in the cannabis plant. THC
is associated with psychosis, anxiety, and depression symptoms, which leads to the inevitable
exacerbation of underlying psychiatric disorders (Monte et al., 2015 & ElSohly et al., 2018). There
is a lack of laboratory-based data that directly evaluates the psychological effects of cannabinoid
compounds (D’Souza et al., 2004). The endocannabinoid system consists of endogenous
cannabinoids, cannabinoid receptors, and the synthetic and degrading enzymes responsible for the
synthesis and degradation of endocannabinoids (Mackie, 2008). The endocannabinoid system is
an important pathway for the regulation of appetite and emesis (Martin, 2002, Di Marzo et al.,
2001, Darmani et al., 2003, Darmani, 2001, Sharkey et al., 2014, Schlicker & Kathmann, 2001, &
Howlett et al., 2002). Cannabinoids activate the same receptors as endocannabinoids (ElSohly et
al., 2000). The identification of cannabinoid receptors grew out of a desire to understand the
psychoactive effects of THC. A binding assay for this receptor showed high levels of receptors
present in certain brain regions (Mackie, 2008).
Ingestion of marijuana results in THC metabolites in the urine of the person using the
substance. The methods of drug testing for marijuana work based on the detection of THC carboxy
metabolite in the urine. This has been a relatively effective and reliable method (Elsohly et al.,
2011). Drug users have been trying to evade the detection of marijuana use by contamination
(Elsohly et al., 1997 & Tsai et al., 1998). Drug testing programs have now implemented specimen
validity testing as part of their drug testing protocol (Elsohly et al., 2011).
Synthetic cannabinoids are a heterogeneous group of compounds developed to investigate
the endogenous cannabinoid system or as potential medicines. Covert laboratories used published
data to develop variations in synthetic cannabinoids marketed as designer drugs that could be
abused. Synthetic cannabinoids because popular in the early 2000’s because of their ability to

3

escape detection by standard cannabinoid screening tests. The majority of synthetic cannabinoids
detected in herbal products have a greater binding affinity to the cannabinoid CB1 receptor than
does THC. They also show a greater affinity at the CB1 receptor than the CB2 receptor. Synthetic
cannabinoids are more potent than THC, therefore, creating more intense psychoactive effects.
There is a need for further study pertaining to these compounds (Castaneto et al., 2014, Castaneto
et al., 2015, & Gandhi et al., 2015). The three synthetic cannabinoids being studied in this
experiment are JWH-302, JWH-237, and mepirapim.
JWH-302 (1-pentyl-3-(3-methoxyphenylacetyl) indole) is an analgesic chemical from the
phenlacetylindole family. This acts as a cannabinoid agonist with a moderate affinity at both the
CB1 and CB2 receptors. This synthetic cannabinoid is a possible isomer of the more common drug
JWH-250. JWH-302 is less potent with a Ki of 17 nM at the CB1 receptor compared to a Ki of 11
nM for JWH-250 (Manera et al. 2008). These two compounds have identical molecular weight
and similar fragmentation patterns. It is quite difficult to distinguish between these two using GCMS testing (Huffman et al. 2005). This substance is a Schedule I controlled substance. The
structures of both JWH-302 and JWH-250 are shown in Figure 1 in order to compare the two.
The only difference between JWH-302 and JWH-250 is the orientation of the methoxy group: meta
for JWH-302 and ortho for JWH-250.
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Figure 1. Structure of JWH-302 on the left and JWH-250 on the right.1

JWH-237 (2-(3-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-one) is also known as
JWH-203 3-chlorophenyl isomer. JWH-237 is an analog of the phenylacetylindole cannabinoid
agonist JWH-203. JWH-203 acts as a cannabinoid receptor at both the CB1 and CB2 receptors. It
has a phenylacetyl group in place of the naphthoyl ring used in most aminoalkylindole cannabinoid
compounds and has the strongest in vitro binding affinity for the cannabinoid receptors of any of
the synthetic compounds in the phenylacetyl group. While JWH-203 has been studied, the activity
of JWH-237 has not yet been determined (Huffman et al., 2005). The structures for JWH-237 and
JWH-203 are shown in Figure 2. They are presented side by side for comparison. The only
difference is in the position of the chlorine atom. In JWH-237 the chloride atom is meta, and in
JWH-203 the chloride atom is ortho.

1

Figures of all three synthetic cannabinoids and synthetic cannabinoids used for comparison are
placed in the supplementary information section for easy access
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Figure 2. Structures of JWH-237 on the left and JWH-203 on the right.

Mepirapim (4-methylpirperazin-1-yl)-(1-pentylindol-3-yl)methanone) is an indole-based
cannabinoid. It differs from JWH-018 by having a 4-methylpiperazine group in place of the
naphthyl group. More is known about JWH-018 because it is a more researched compound because
of its large prominence in spice and K2 (ElSohly et al., 2011). JWH-018 has an affinity for the
cannabinoid receptor that is five times greater than that of THC. It is from the naphthoylindole
family and acts as a full agonist at the CB1 and CB2 receptors. It has some selectivity for the CB2
receptor. This compound works by mimicking the endocannabinoid hormones that the body
naturally produces. This can cause either inhibition or activation of nerve signaling (Brents et al.,
2013). Mepirapim has been used as an active ingredient in synthetic cannabinoid products. It was
first identified in Japan in 2013 alongside FUBIMINA (Uchiyama et al., 2014). The structures of
mepirapim, JWH-018, and FUBIMINA are shown in Figure 3-4. The difference between the two
compounds comes from the mepirapim having 4-methylpiperazine group instead of the naphthyl
group.
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Figure 3. Structure of mepirapim on the left and JWH-018 on the right.

Figure 4. Structure of FUBIMINA.

This is a part of a larger product that aims to study the effects of synthetic cannabinoids
compared to THC on the renal and cardiovascular systems using animal studies. After this project
is complete, another group of undergraduates will take this study further to study the effects of
synthetic cannabinoids and THC on the renal and cardiovascular systems in rat models. Instead of
using rat models, this study will use human liver microsomes. The use of the human liver
microsomes can help characterize these compounds and show how the liver metabolizes these
compounds (Human and Animal Liver Microsomes Thawing and Incubation Protocol). The liver

7

is the largest internal organ in the human body, located between the digestive tract and the other
parts of the body. The liver is rich is heme-containing enzymes, CYP450. This enzyme plays a big
role in phase I oxidation reactions. CYPs can transform nontoxic chemicals into reactive
intermediates that are toxic (Asha et al., 2009). The liver metabolizes endogenous substrates as
well as exogenous drugs (Human and Animal Liver Microsomes Thawing and Incubation
Protocol).
Human liver microsomes contain a wide variety of drug metabolizing enzymes and are
commonly used in support in vitro absorption, distribution, metabolism, and excretion studies
(Human Liver Micrsomes). There are several in vitro tools that are available for researches to study
the metabolic fate of drugs. These include liver slices, cryopreserved hepatocytes, and subcellular
fractions such as liver microsomes and S9 fractions (Human and Animal Liver Microsomes
Thawing and Incubation Protocol). Human liver microsomes are used for the evaluation of phase
I oxidation with the addition of a cofactor like NADP+. Liver micrsomes can be prepared using
liver slices, cell lines, and primary hepatocytes. Human liver microsomes can be used to identify
critical CYP involved in the metabolism of the drug. It is advantageous to use human liver
micrsomes because of the low cost, simplicity of use, easy storage, best characterized in vitro
model for drug metabolism research, and enzyme activity can be kept frozen for many years (Asha
et al., 2009).
The liver microsomes are prepared from the liver through a series of homogenization and
ultracentrifugation. Lower speed centrifugation of liver homogenate at 10,000g produces the
supernatant, which is known as the S9 fraction. The S9 fraction contains all phase I and phase II
enzymes. Further centrifugation at 100,000g yields the endoplasmic reticulum derived
microsomes. Microsomes are an enriched source of cytochrome P450 (CYP) and flavin

8

monooxygenase (FMO) enzymes. Some phase II enzymes, certain uridine glucuronide transferases
(UGT) isoforms and epoxide hydrolase (EH) enzymes are present, as well in the microsomes.
Individual or pooled donor microsomes can be used for metabolism-related studies. Pooled donors
can represent the average human population or particular factors of research interest (Human and
Animal Liver Microsomes Thawing and Incubation Protocol). Human liver micrsomes are
prepared by differential centrifugation and stored at -80 °C until use. The microsomes are
incubated with a mixture consisting of NADPH generating compounds, NADP+ and glucose-6phosphate dehydrogenase. The addition of compounds to create the NADPH system initiates the
reaction. There is also the addition of buffers like a potassium phosphate buffer (Asha et al., 2009).
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MATERIALS AND METHODS
Preparation of Stock Solutions
A series of stock solutions had to be prepared before the start of the work with the human liver
microsomes. These solutions included a potassium phosphate buffer, a NADP+ solution, a glucose6-phosphate solution, a magnesium chloride solution, and a glucose-6-phosphate dehydrogenase
solution. In order to create the 1 M potassium phosphate buffer with a pH of 7.4, two solutions
were created using dibasic and monobasic potassium phosphate. Both potassium phosphate
monobasic and potassium phosphate dibasic were obtained from Sigma-Aldrich. The first solution
of 1 M of potassium phosphate dibasic (K2HPO4) was created by mixing 17.42 grams of K2HPO4
with 100 mL of deionized water. The second solution of 1 M of potassium phosphate monobasic
(KH2PO4) was created by mixing 13.60 grams of KH2PO4 with 100 mL of deionized water. The
pH of 7.4 was created by the addition of 80.2 mL of K2HPO4 and 19.8 mL of KH2PO4. The next
solution that was created was the 50 mM NADP+ solution. A total of 0.0783 grams was added to
2 mL of water to create the solution. The sample was separated into aliquots: 5 vials of 100 µL
and 8 vials of 300 µL. The next solution prepared was the 100 mM G6P solution. A total of 0.1855
grams of G6P was added to 6 mL of water. The sample was separated into aliquots: 3 vials of 350
µL and 3 vials of 1200 µL. The G6PD was used directly from Sigma-Aldrich. It was prepared as
200 units/mg of protein. Aliquots were created: 5 vials of 50 µL and 5 vials 150 µL. The last
solution prepared was the 1 M magnesium chloride solution. A total of 0.2845 grams of MgCl2
was dissolved in 3 mL of water. The dissolved solution was separated into aliquots: 10 vials of 50
µL and 5 vials of 400 µL.
Preparation of Positive Controls
A positive control is a group in an experiment that receives treatment with a known result, and
therefore should show a particular change during the experiment. It is used to control for unknown
10

variables in the experiment and to give something to compare with the test group. The purpose of
the positive control was to see if the test compounds would be metabolized by the human liver
microsomes with the method used. Two different positive controls were used for the experiment:
THC and testosterone. The total volume of the reaction mixture was 1.5 mL. This reaction mixture
(1.5 mL) was prepared by mixing 30 µL of NADP+ (1 mM), 150 µL of G6P (10 mM), 15 µL of
G6PD (2 U/mL), 15 µL of MgCl2 (10 mM), 150 µL of KPO4 buffer (100 mM), and 75 µL of
human liver microsomes. This was done twice for the two positive controls. The amount of THC
and testosterone added to the mixture was calculated for the 1.5 mL mixture. This calculation led
to the addition of 4.7 µL of THC (10 µM) and 1.5 µL of testosterone (10 µM). The solution was
diluted with water to bring it to the 1.5 mL volume. The solution was agitated in the shaking water
bath at 37 ˚C. A total of nine samples of 100 µL of each solution was collected at intervals of 15
minutes starting at 0 up until 2 hours. A total of 200 µL of ice-cold acetonitrile was added to the
solutions at the time the sample was collected to stop the reaction. The samples were vortexed for
2 minutes. After the vortex, the samples were incubated at -60 ˚C for 1 hour. The samples were
then centrifuged at 16128 RCF for 15 minutes. The clear supernatant was collected and analyzed
using LC/MS/MS.
Preparation of Negative Control
The preparation of the negative control had all the components present in the positive controls and
reaction except for the liver microsomes. Since the negative control does not contain liver
microsomes, there should be no response in terms of the metabolism of the test compound. It
controls the unknown variable during the experiment and provides something to compare with the
test group. The negative control was prepared by adding a total of 30 µL of NADP+ (1 mM), 150
µL of G6P (10 mM), 15 µL of G6PD (2 U/mL), 15 µL of MgCl2 (10 mM), and 150 µL of KPO4
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buffer (100 mM). A total of 4.7 µL of THC was added to the mixture. Water was added to the
compound to make up for the loss of volume from human liver microsomes and to bring the
volume to 1.5 mL. The same procedure was performed for the negative control. The solution was
agitated in the shaking water bath at 37 ˚C. A total of nine samples of 100 µL of each solution was
collected at intervals of 15 minutes starting at 0 up until 2 hours. A total of 200 µL of ice-cold
acetonitrile was added to the solutions at the time the sample was collected to stop the reaction.
The samples were vortexed for 2 minutes. After the vortex, the samples were incubated at -60 ˚C
for 1 hour. The samples were then centrifuged at 16128 RCF for 15 minutes. The clear supernatant
was collected and analyzed using LC/MS/MS.
Preparation of Vehicle Control
The vehicle control is used in studies in which a substance (e.g., saline, mineral oil, organic
solvents) is used as a vehicle to dissolve the experimental compound. For the vehicle control, the
substance is administered in the same manner in which it will be used with the experimental
control. For the positive control of THC in this experiment, methanol was used as a vehicle. For
the other compounds in the experiment, DMSO was used as the vehicle. The vehicle control was
a reaction mixture of 1.5 mL. The reaction mixture was prepared by adding a total of 30 µL of
NADP+ (1 mM), 150 µL of G6P (10 mM), 15 µL of G6PD (2 U/mL), 15 µL of MgCl2 (10 mM),
150 µL of KPO4 buffer (100 mM), and 75 µL of human liver microsomes. Depending on the
compound used, either 4.7 µL of methanol or 1.5 µL of DMSO was added to the reaction mixture.
The same procedure was further followed as mentioned above to collect and analyze samples for
LC/MS/MS. The solution was agitated in the shaking water bath at 37 ˚C. A total of nine samples
of 100 µL of each solution was collected at intervals of 15 minutes starting at 0 up until 2 hours.
A total of 200 µL of ice-cold acetonitrile was added to the solutions at the time the sample was
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collected to stop the reaction. The samples were vortexed for 2 minutes. After the vortex, the
samples were incubated at -60 ˚C for 1 hour. The samples were then centrifuged at 16128 RCF for
15 minutes. The clear supernatant was collected and analyzed using LC/MS/MS.
Preparation of Synthetic Cannabinoids
The three synthetic cannabinoids – JWH-302, JWH-237, and mipirapim – were obtained from
Cayman Chemicals. JWH-302 was prepared as a 5 mg solution in methyl acetate. The solution
was diluted to 5 mM with the addition of 33.5 µL of JWH-302 from Cayman Chemicals with 966.5
µL of DMSO. JWH-237 was prepared as a 5 mg solution in methanol. The solution was diluted to
5 mM with the addition of 33.99 µL of JWH-237 with 966.0 µL of DMSO. Mepirapim was
prepared as a 5 mg crystalline solid. The 5 mg solid was mixed with 2.86 mL of DMSO.
Reaction with Synthetic Cannabinoids
The test compounds for the reaction were prepared in the same method as the positive controls. A
total of 30 µL of NADP+ (1 mM), 150 µL of G6P (10 mM), 15 µL of G6PD (2 U/mL), 15 µL of
MgCl2 (10 mM), 150 µL of KPO4 buffer (100 mM), and 75 µL of human liver microsomes were
mixed together. This was done in three different vessels for the three compounds: JWH-302, JWH237, and mipirapim. A total of 3 µL of the test compound was added. One of the three test
compounds was added to each of the vessels. The solution was diluted with water to bring it to the
1.5 mL volume. The solution was agitated in the shaking water bath at 37 ˚C. A total of nine
samples of 100 µL of each solution was collected at intervals of 15 minutes starting at 0 up until
2 hours. A total of 200 µL of ice-cold acetonitrile was added to the solutions at the time the sample
was collected to stop the reaction. The samples were vortexed for 2 minutes. After the vortex, the
samples were incubated at -60 ˚C for 1 hour. The samples were then centrifuged at 16128 RCF for
15 minutes. The clear supernatant was collected and analyzed using LC/MS/MS.
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RESULTS AND DISCUSSION
Instrumentation Theory
In this experiment, THC was subjected to in vitro human liver microsomal metabolism in
which the compound was incubated with the microsomes for 30 minutes at 37 ºC in the presence
of NADP+ and G6PD. The THC (positive control) and negative control were analyzed using
LC/MS/MS after the extraction of the reaction mixture. The instrument used in this lab was the
AB SCIEX 3200 mass spectrometer using MRM with ESI, attached with a Shimadzu HPLC using
a Phenomenex C-18 reverse phase column. Water and acetonitrile, both with 0.1% formic acid,
were used as solvents. LC/MS/MS is the most common bioanalytical method in use today. It is a
very versatile, robust, and sensitive method. The AB SCIEX 3200 is best suited for quantitative
and qualitative analysis of small molecules and qualitative analysis of proteins and peptides. This
experiment largely focuses on the quantitative analysis of small molecules with the molecular
weight of the synthetic cannabinoids in addition to the resulting metabolites.
HPLC uses high pressure to push samples through a chromatography column to separate
the compounds that make up the sample. A reverse phase column was used in this experiment.
This is the opposite of normal phase, but it also separates molecules based on polarity. It does this
through the use of a non-polar stationary phase and a polar mobile phase. The molecules were
eluted from the chromatography column under high pressure. The continuous flow cannot be
directly detected by the mass spectrometer because they operate in a vacuum and require liquid to
be passed through an interface. The interface removes the mobile phase used in the
chromatography step and transfers the analyte to the mass spectrometry unit. The interface used in
this experiment is an electrospray ionization (ESI) system. The liquid is nebulized into a fine spray,
ionized, and transferred to the mass spectrometer detector.
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A triple quadrupole mass spectrometer was used in this experiment. The mass spectrometry
detector measures the mass-to-charge (m/z) ratio of the compounds by exposing the ions to a
magnetic or electric field, which alters the movement of the compounds. This movement allows
the analysis based on mass. The use of two mass spectrometer detectors allows for molecules with
certain m/z ratios to be sorted through and further analyzed by fragmenting. High-sensitivity
multiple reaction monitoring is used for this experiment. MRM involves a MS/MS scan where an
ion is passed through the Q1 quadrupole and fragmented in the Q2 collision cell; the Q3 quadrupole
is then used to specify which fragment ion can reach the detector. The mass spectrum of the sample
will provide information about the structural and chemical properties of the synthetic cannabinoids
used in this experiment. A schematic for LC/MS/MS obtained from ResearchGate is shown in
Figure 5.

Figure 5. Schematic for LC/MS/MS

15

Standards
An internal standard for THC was run before the controls in order to confirm the
metabolites obtained in our sample. The compounds for each of the retention times for the THC
standard were identified in Figure 6. The THC was metabolized into three major metabolites: 11nor-9-carboxy-∆9-tetrahydrocannabinol (THC-COOH), 11-hydroxy-∆9-tetrahydrocannabinol (11OH-THC), and cannabidiol (CBD). These compounds are labeled. The structure of THC is shown
in Figure 7 and the structures of its metabolites are shown in Figures 8-10. The progression of the
metabolism of THC went from THC to 11-OH-THC to THC-COOH. The following transition ions
were monitored by multiple reaction monitoring (MRM): m/z 314.960 > 193.050 Da and 314.960
> 122.880 Da for THC/CBD/CBC, m/z 331.300 > 201.200 Da and 331.300 > 193.200 Da for 11OH-THC, m/z 345.200 > 299.100 Da and 345.200 > 193.100 Da for THC-COOH.

THC-COOH

11-OH-THC

THC
CBD

Figure 6. LC/MS/MS chromatogram of the THC standard. THC and its metabolites are labeled
in the chromatogram. The right side of the chromatogram has the deuterated samples.
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Figure 7. Structure of THC

Figure 8. Structure of 11-OH-THC

Figure 9. Structure of THC-COOH
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Figure 10. Structure of cannabidiol

THC Positive Control
The retention times (RT) present in the internal standards were compared with the
LC/MS/MS results obtained from the THC positive control. The LC/MS/MS retention times
shown in the standard matched with the retention times from the THC positive control. The THC
positive control was measured in 9 aliquots that varied with the time that the reaction was run. The
samples of THC started at 0 minutes and went to 2 hours in 15-minute increments. Figures 11-19
show the results for the LC/MS/MS. Figure 11 is the THC at 0 minutes, Figure 12 is the THC at
15 minutes, Figure 13 is the THC at 30 minutes, and continues in 15-minute increments until
Figure 19 with the THC at 2 hours. Through the attenuated changes in the intensity of the THC
peak located at a RT of 4.96 present in the data with time, it is shown that THC becomes fully
metabolized around one hour.
There is a high-intensity peak present at 0 minutes with a RT of 4.95. The intensity of the
peak was 24000 cps with a mass of m/z 314.96 Da. This indicates the strong presence of THC.
There is also a very weak intensity peak (approximately 1500 cps) present with a retention time of
4.51 and a mass of m/z 331.300 Da. The m/z indicates the presence of 11-OH-THC. This is shown
in Figure 11. As the time changes to 15 minutes, the high-intensity peak now becomes less intense
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(4.95 RT and intensity of 600 cps). The less intense peak becomes more intense (4.51 RT and
intensity of 2868 cps). This indicates that most of the THC is getting converted into 11-OH-THC.
This is shown in Figure 12. The THC and 11-OH-THC peaks are still visible in the data at 30
minutes, but the intensity has decreased to around 278 and 351, respectively. The low level of
intensity shows that the THC and 11-OH-THC are converted into other metabolites. The additional
peak at 4.49 RT indicates the presence of THC-COOH. This is shown in Figure 13. At 45 minutes,
there is no longer a THC peak present at 4.95 RT. However, the other metabolites previously
mentioned were found at low intensity. This is shown in Figure 14. It is shown in Figure 15 that
there are no prominent THC peaks. The intensity of the peaks changes from being 24000 cps to
278 cps. The peak present for the THC at 0 minutes at a RT of 4.95 is no longer visible in the data.
The peaks from the LC/MS/MS do not change after the 1-hour mark; the peaks remain similar for
the next four collections. This is shown in Figures 16-19. The positive control data show that the
method being used is appropriate for the experiment and that the human liver microsomes were
successful in metabolizing THC.
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11-OH-THC

THC

Figure 11. LC/MS/MS chromatogram of the THC positive control at 0 minutes. There is a strong
peak present for THC at an intensity at 24,000 cps. There is weak peak already present at 1500 cps
for 11-OH-THC. The THC has is spontaneously metabolizing into 11-OH-THC.
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11-OH-THC

THC

Figure 12. LC/MS/MS chromatogram of the THC positive control at 15 minutes. The THC peak
has decreased in intensity to 600 cps. The 11-OH-THC peak has increased in intensity to 2868 cps.
This means that the THC is being metabolized into 11-OH-THC.
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11-OH-THC

THC

Figure 13. LC/MS/MS chromatogram of the THC positive control at 30 minutes. Both the THC
and the 11-OH-THC peak have decreased in intensity. THC was being metabolized into 11-OHTHC, and the 11-OH-THC was being metabolized further.
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THC-COOH

Figure 14. LC/MS/MS chromatogram of the THC positive control at 45 minutes. There are no
longer peaks present for THC or 11-OH-THC. This means that the THC and the 11-OH-THC have
completely been metabolized. There is also a peak present for THC-COOH from the metabolism
of 11-OH-THC.
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Figure 15. LC/MS/MS chromatogram of the THC positive control at 1 hour. There are no longer
any peaks present for THC or its metabolites. THC and its metabolites have been completed
metabolized. After the 1 hour mark, the chromatograms look around similar for the next hour.
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Figure 16. LC/MS/MS chromatogram of the THC positive control at 1 hour 15 mintues

Figure 17. LC/MS/MS chromatogram of the THC positive control at 1 hour 30 minutes
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Figure 18. LC/MS/MS chromatogram of the THC positive control at 1 hour 45 minutes

Figure 19. LC/MS/MS chromatogram of the THC positive control at 2 hours
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Negative Control
The negative control was performed with all the components used in the experiment except
for the pooled human liver microsomes. The negative control was measured at 0 minutes, 1 hour,
and 2 hours. The LC/MS/MS data for these are shown in Figures 20-22. The negative control was
analyzed in order to confirm that the method did not have confounding variables. It was important
that the metabolism that occurred was a result of the human liver microsomes and not caused by
the other compounds that were used in the experiment. It was confirmed by the LC/MS/MS that
the human liver microsomes were responsible for metabolizing the test compound. The analysis
of the THC did not change throughout the time interval. All three graphs showed similar activity.
The THC peak at the retention time of 4.95 remained prominent throughout the 2 hours.

THC

Figure 20. LC/MS/MS chromatogram of the THC negative control at 0 minutes. There is a peak
present at an intensity of 17,400 cps for THC.
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11-OH-THC

THC

Figure 21. LC/MS/MS chromatogram of the THC negative control at 1 hour. The THC peak has
decreased in intensity to 5842 cps. There is also a peak present at 259 cps for 11-OH-THC. The
THC is being metabolized into its metabolite 11-OH-THC.
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11-OH-THC

THC

Figure 22. LC/MS/MS chromatogram of the THC negative control at 2 hours. The THC peak has
further decreased in intensity to 3000 cps. The peak for 11-OH-THC increased in intensity to 400
cps. The THC is being metabolized further into its metabolite 11-OH-THC.
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Further Experiment Halted by COVID-19
The experimental procedure was conducted up to the point of the preparation of the
synthetic cannabinoid samples. The reaction mixtures with the three novel synthetic cannabinoids
were never able to be prepared and analyzed because of the closure of the chemistry department
for safety reasons concerning COVID-19. This portion was still included in the procedure for the
completeness purposes. The purpose for completing this research was to test the metabolism of
the three novel synthetic cannabinoids (JWH-302, JWH-237, and mepirapim) in human liver
microsomes. If the LC/MS/MS chromatogram for the three synthetic cannabinoids could have
been obtained, an analysis similar to the one performed for the THC positive control would have
been included in this thesis. It is quite disappointing that all the literary reviews and work done to
find novel compounds never led to a completed final product. While it saddens me to turn in a
thesis that does not reach my initial expectations, I am proud that I was able to have some research
to present.
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CONCLUSION
The purpose of this experiment was to characterize the metabolites of THC and three other
synthetic cannabinoids metabolized by human liver microsomes. The three novel synthetic
cannabinoids JWH-302, JWH-237, and mepirapim were not analyzed using LC/MS/MS because
of the constraints placed on the chemistry department and The University of Mississippi due to
COVID-19. The reaction mixtures that were prepared before the pandemic included the THC
positive control and negative control. These two reaction mixtures were analyzed using liquid
chromatography with tandem mass spectrometry (LC/MS/MS). A LC/MS/MS chromatogram for
a THC standard was obtained before analyzing the controls. The chromatogram for the standard
showed the THC and its subsequent metabolites. The LC/MS/MS chromatogram for the THC
positive control showed a high intensity peak at 4.95 RT at time zero. After 15 minutes had elapsed,
the THC peak at 4.95 RT attenuated to approximately 700 cps while the THC metabolite, 11-OHTHC at RT 4.51, peak increased from 1500 cps to 2868 cps. At the 30-minute mark, there are two
really weak peaks present that represent THC (approximately 280 cps) and 11-OH-THC
(approximately 350 cps). The low intensity of the peaks indicated that most of the THC and 11OH-THC had been converted into other metabolites. 11-COOH-THC is present with a peak with
a retention time of 4.49. There is no longer a THC peak present at 45 minutes, incidating that all
of the THC had been matabolized. The positive control showed that the method being used is
appropriate for the experiment and that the human liver microsomes were successful in
metabolizing THC. No changes were observed in the LC/MS/MS chromatograms for the negative
control which suggests that no metabolism of the test compound occurred in the absence of human
liver microsomes. This is evident through the presence of the 4.95 RT of THC peak throughout
the 2 hours.
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SUPPLEMENTARY MATERIAL

JWH-250

JWH-302

JWH-237

JWH-203

mepirapim

JWH-018
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FUBIMINA
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